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INTRODUCTION
Metabolic diseases often disrupt normal cellular processes in the heart and result in cardiac dysfunction, life-threatening arrhythmias, and ultimately increased mortality [1, 2] . Frequently, metabolic diseases are categorized to inborn errors of metabolism (IEM) and acquired metabolic syndrome, the latter of which is defined as a group of risk factors that raise the risk of heart disease in adulthood. In-vitro modeling of cardiometabolic diseases utilizing human cardiac tissue has posed a challenge because of morbidity associated with tissue biopsy and lack of tissue availability. Animal models have enabled critical advances in understanding the biology of heart diseases, but there remain questions of translatability to humans because of interspecies differences in physiology [3] . Additionally, recapitulating accurate phenotypes of IEM in vivo has been challenging because transgenic animal models of these disorders are often nonviable with early mortality. Finally, metabolic syndrome is polygenic in nature and influenced by epigenetic or environmental factors, and therefore it has been difficult to model the disease using transgenic techniques.
Since its advent in the mid-2000s, induced pluripotent stem cell (iPSC) technology has provided investigators with a new methodology to model pathophysiology of heart diseases and thereby identify novel therapeutic targets [4, 5] . In recent years, researchers have studied various cardiomyopathies and cardiac channelopathies using patient-specific iPSC-derived cardiomyocytes (iPSC-CMs) [6 & ], including arrhythmogenic right ventricular cardiomyopathy [7, 8] , familial dilated cardiomyopathy (DCM) [9] [10] [11] , familial hypertrophic cardiomyopathy (HCM) [12] , and long QT syndrome [13] [14] [15] . Advances in replicating significant mutation-induced dysregulation of cells using iPSC-CM platforms have also allowed the study of deleterious metabolic diseases in a petri dish (Fig. 1a ). This review will encapsulate the current standing of iPSC-based disease modeling for IEM ( Fig. 1b ) and common metabolic syndromes, and how ultimately the iPSC field can attain the goals of personalized medicine, to understand and treat disease at a patient-specific level [16] .
CARDIOMYOPATHY WITH INBORN ERRORS OF METABOLISM
IEM are heritable monogenic disorders that often present congenitally with multisystem manifestations affecting various organs, including the heart, nervous system, and skeletal muscle. Mutations in IEM commonly disrupt energy metabolism, such as glycogen and lysosomal storage, lipid metabolism, fatty acid oxidation and transport, and respiratory chain function. Studies have shown that approximately 5% of IEM have associated cardiac morbidity and mortality [1] . Cardiac involvement in IEM often
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Inborn errors of metabolism with significant cardiomyopathy have been modeled using iPSC-CMs.
Acquired metabolic syndromes, such as diabetes mellitus cardiomyopathy and ischemic cardiac changes associated with aldehyde dehydrogenase 2 polymorphism, have been modeled using iPSC-CMs. . Current iPSC-CM models of inherited errors in metabolism. (a) A schematic view of the process to recapitulate metabolic heart disease in a dish, with steps to reprogram human peripheral blood mononuclear cells (PBMCs) to iPSCs and then differentiate to cardiomyocytes. (b) Cellular metabolic processes in inborn errors of metabolism successfully recapitulated in iPSC-CMs with correlated in-vitro phenotypes. Pompe disease (glycogen storage disorder type II) showed glycogen accumulation in lysosomes. Danon disease (glycogen storage disorder type IIb) showed defects in early autophagosome vacuoles and resultant cellular hypertrophy. Barth syndrome (mitochondrial disorder) showed impaired cardiolipin remodeling resulting in reduced mitochondrial supercomplex formation. Fabry disease (lysosomal storage disorder) showed increased glycosphingolipid accumulation in lysosomes. ER, endoplasmic reticulum; GAA, acid a-glucosidase; iPSC-CM, induced pluripotent stem cell-derived cardiomyocyte.
Pompe disease
Pompe disease is an autosomal recessive, type II glycogen storage disease resulting from complete loss of acid a-glucosidase (GAA), which hydrolyzes glycogen to glucose [26, 27] . Significant cellular and ultrastructural pathology observed with electron microscopy is caused by abnormal accumulation of lysosomal glycogen primarily in cardiac and skeletal muscle, causing predominantly cardiac hypertrophy. Enzyme replacement therapy (ERT) using recombinant human GAA (rhGAA) has been a mainstay therapy for Pompe disease patients [28] . However, ERT is not curative, with varying degree of response, and has adverse effects such as immunologic reactions and life-threatening arrhythmias, warranting efforts to further understand the pathophysiology of Pompe disease with iPSC modeling. Huang et al. [17] first modeled Pompe disease in iPSCs by conditionally overexpressing GAA at the time of reprogramming to evade initial metabolic defects of the GAA mutation and allow successful generation of iPSCs from two patients with infantile-onset Pompe disease. Mutant Pompe disease iPSCs exhibited ultrastructural abnormalities and mitochondrial dysfunction. Upon differentiation into cardiomyocyte-like cells, the cells reconstituted cardinal features of Pompe disease, showing a twofold increase in glycogen content, deteriorating mitochondria, and formation of autophagosomelike structures. When treated with rhGAA, Pompe disease iPSC-CMs demonstrated positive functional response with significant reduction in glycogen. Additionally, several molecular markers were found to be up-or down-regulated with rhGAA therapy, which could offer options for monitoring therapeutic response in Pompe disease patients.
Raval et al. [19 & ] then used iPSC-CMs derived from two patients with infantile-onset Pompe disease to further investigate its underlying molecular mechanisms. In normal physiological states, the lysosome degrades intracellular pathogens, damaged organelles, and proteins via the autophagy pathway. In this study, Pompe disease iPSC-CMs were found to have normal autophagic function but exhibited a deficit of Golgi-based protein glycosylation. The resultant defective glycosylation, as observed in the lysosome-associated membrane proteins (LAMPs), was then linked to hypertrophic remodeling, which provided novel pathophysiologic insight into the development of cardiomyopathy associated with Pompe disease.
Danon disease
Danon disease is an X-linked, type IIb glycogen storage disorder associated with skeletal dysfunction and a myriad of heart diseases, including HCM, DCM, and increased arrhythmogenicity [29] . Deficient mutations in the LAMP-2 gene prevent complete fusion of lysosomes and autophagosomes, resulting in impaired autophagy. Two patientspecific iPSC-CMs with LAMP-2 gene mutations were generated and compared with a rescued cell line with overexpression of a common Danon disease isoform, LAMP-2B (LAMP 2B OE) [21] . The Danon iPSC-CMs exhibited key features of heart failure, including cellular hypertrophy, delayed calcium handling, and increased oxidative stress, which were then absolved in the LAMP-2B OE cells. Additionally, a significant decline in mature autophagocytic vacuoles in Danon iPSC-CMs compared with LAMP-2B OE was observed, suggestive of impaired autophagy because of LAMP-2 deficiency. Treatment of Danon iPSC-CMs with antioxidant therapy resulted in significantly reduced apoptotic and stress response events. This study unraveled a mechanism of LAMP-2 in cardiac disorder of Danon disease and revealed a prospective therapy. In the future, functional correction of deficient LAMP-2 with genome editing techniques could be conducted in similar models to further study diseased and rescued characteristics.
Mitochondrial disease
Barth syndrome Barth syndrome (BTHS) is an X-linked mitochondrial disorder with mutations in tafazzin (TAZ1), a phospholipid acyltransferase that impairs remodeling of cardiolipin to its mature form. As cardiolipin is a primary constituent of the mitochondrial membrane, TAZ1 mutations result in a characteristic triad of disease: cardiomyopathy, skeletal myopathy, and neutropenia [30] . The first BTHS patientspecific iPSCs were derived from three patients with TAZ1 mutations [22] . Reprogrammed BTHS iPSCs displayed impaired cardiolipin remodeling, with decreased levels of mature cardiolipin leading to scarce formation of mitochondrial supercomplexes and subsequent incomplete energy transformation.
Wang et al. [23 && ] then investigated whether restoration of TAZ levels via transfection with modified RNA would rescue the phenotype. Cellular contractility and sarcomerogenesis were studied using three cell lines: 'diseased' BTHS iPSC-CMs derived from two patients harboring either a missense or frameshift TAZ mutation; 'rescued' BTHS iPSC-CMs by transfection with synthetic modified RNA to restore TAZ levels; and 'induced' BTHS iPSC-CMs by 'clustered regularly interspaced short palindromic repeats' (CRISPRs)/Cas-9 mediated genome editing to create a pathogenic mutant TAZ. Although irregular alignment of sarcomeres was observed in both 'diseased' and 'induced' BTHS iPSC-CMs, restoration of intact sarcomerogenesis was seen in the 'rescued' cell lines. Intriguingly, there was variability in sarcomere organization with respect to mutation types, with the TAZ frameshift mutation showing more pronounced disorganization than the missense mutation. This finding suggests a wide spectrum of disease phenotypes based on different mutations and highlights the feasibility of iPSC technology to correlate specific mutant types with in-vitro phenotypes to further predict disease severity as well as response to therapy. Similar results were observed on thin tissue constructs generated from iPSC-CMs, called 'hearton-a-chip,' which allows investigation of cardiomyocyte contractile properties including twitch stress, and diastolic and peak systolic stresses in vitro [23 && ]. Using this method, the authors found a significant decline in contractility with lower twitch and peak systolic stress in both 'diseased' and 'induced' BTHS iPSC-CM compared with 'rescued' cells. When these cells were treated with precursors of cardiolipin, such as linoleic acid, or with the antioxidant mitoTEMPO, there was profound improvement in sarcomeric organization and contractile dysfunction, suggesting potential therapeutic opportunities.
Lysosomal storage disorder
Fabry disease Fabry disease is an X-linked lysosomal storage disorder caused by deficiency in a-galactosidase A (GLA) with consequent accumulation of globotriaosylceramide (GL-3) in the heart, brain, and kidneys, leading to damage of these organs [31] . Recently, Itier et al. [25] derived Fabry disease iPSC-CMs from two patients with GLA mutations to understand the role of GL-3 accumulation in the pathogenesis of Fabry disease-associated cardiomyopathy. The Fabry disease iPSC-CMs demonstrated progressive lysosomal accumulation of GL-3, increased lysosomal storage inclusions (zebra bodies), and disorganized contractile fibers. Presently, ERT with a-galactosidase A is the primary treatment strategy available for Fabry disease by degrading GL-3 and thereby reducing its tissue accumulation; however, longterm reduction of GL-3 was not observed. Investigators sought to identify a novel sustained treatment of GL-3 reduction utilizing the Fabry disease iPSC-CM model. Substrate reduction therapy (SRT) inhibits glucosylceramide synthase, a rate-limiting step in glycosphingolipid synthesis, and was postulated to be a potential alternative therapy to ERT, with encouraging results in animal models. When tested in iPSC-CMs, SRT effectively prevented and reduced GL-3 deposits in Fabry disease cardiomyocytes compared with wild type. These findings confirmed the therapeutic potential of SRT and identified an alternative pathway for GL-3 clearance using a small molecule inhibitor.
Cardiomyopathy associated with acquired metabolic disorder/syndrome
Metabolic syndrome is a constellation of at least three of the following conditions: central obesity, elevated triglycerides, hyperglycemia, hypertension, and reduced high-density lipoprotein. These factors predispose individuals to developing diabetes mellitus and cardiovascular disease (CVD)associated mortality [2] . The recent rise in obesity and insulin resistance with subsequent development of metabolic syndrome necessitates the ability to recapitulate this polygenic disease to better understand its pathogenesis and identify specific treatment options (Table 2) [2, 34] .
Diabetes-induced cardiomyopathy
Diabetes mellitus is a leading cause of cardiac morbidity and mortality with a projected increased prevalence of 300 million individuals by the year 2025 [35] . Individuals with diabetes mellitus have a two to five-fold increased risk for developing heart failure, independent of other known risk factors, such as hypertension or coronary artery disease [36] . In a diabetic state, body metabolism is abnormally driven by fatty acid oxidation rather than glucose and lactate metabolism, leading to lipid accumulation with resultant toxicity to cardiomyocytes. Diabetic cardiomyopathy presents with diastolic or systolic dysfunction, and ultimately advanced heart failure [35] . Causes of diabetic cardiomyopathy are thought to be rather multifactorial, including both epigenetic/environmental factors and genetic predisposition. Given this complex nature of disease, there has been lack of adequate animal models.
Recently, Drawnel et al. [32 & ] modeled a diabetic environment in iPSC-CMs by inducing fatty acid metabolism dependence with initial insulin treatment in the absence of glucose, followed by the addition of diabetic mediators, high glucose, endothelin 1, and cortisol. Diabetes mellitus iPSC-CMs accurately produced features of diabetic cardiomyopathy in vitro, including cellular hypertrophy, abnormal sarcomeric organization, lipid accumulation, decreased calcium transients, and evidence of oxidative stress. Gene expression studies showed upregulation of cellular metabolism genes and downregulation of genes controlling protein synthesis. To study the underlying genetic predisposition of diabetic cardiomyopathy, investigators then generated iPSC-CMs from a patient with fast progression of CVD within 5 years of type II diabetes mellitus versus slow progression of disease (no CVD after 15 years of type II diabetes mellitus). These iPSC-CMs exhibited features of diabetes mellitus phenotypes but with varying extent of in-vitro phenotypic severity. The fast progressive iPSC-CMs showed evidence of sarcomeric disarray, abnormal calcium handling, and lipid-induced toxicity, whereas the slow progressive type displayed only mild sarcomeric disorganization. Gene expression studies comparing fast versus slow progression iPSC-CMs identified upregulation in glucocorticoid signaling and calcineurin-nuclear factor of activated Tcells signaling, which are key signaling pathways in hypertrophic remodeling. The diabetes mellitus iPSC-CM model helped to demonstrate feasibility of iPSC-CM platforms to model polygenic disease, which could open many doors for therapeutic opportunities, including rapid drug screening [32 & ].
Aldehyde dehydrogenase polymorphism and cardiomyocyte Deficiency in the aldehyde dehydrogenase 2 (ALDH2) enzyme is found in about 8% of the population, with a predominance in East Asians, and is most commonly associated with alcohol intolerance, including facial flushing, nausea, and tachycardia [37] . However, deficiency in ALDH2 has also been associated with poor cardiovascular outcomes [33 && ]. This is because during ischemia, oxidative stress ensues, with a rise in reactive oxygen species (ROS), lipid peroxidation, and 4-hydroxynonenal (4HNE), a toxic aldehyde. Normally, ALDH2 functions to detoxify 4HNE and induce vasodilation with nitroglycerin [38] . A defect in ALDH2 function may result in cardiac dysfunction and impaired recovery following an ischemic event. Recently, Ebert et al. [33 && ] evaluated effects of this polymorphism in patient fibroblasts with ALDH2 deficiency versus control fibroblasts. Elevated ROS and 4HNE were observed in the enzyme-deficient cells. When these cells were treated with 4HNE, a toxic aldehyde, there was a decline in cell growth and viability, whereas treatment with Alda-1, a small molecular activator of ALDH2, restored cell growth and viability, suggesting a potential relationship between oxidative stress and cell cycle arrest in ALDH2deficient fibroblasts. To investigate the role of ALDH2 deficiency in cardiomyocytes, patient specific iPSC-CMs were then generated. Similarly to the fibroblast study, when ALDH2-deficient iPSC-CMs were subjected to ischemia, elevation in ROS and reduced cell viability were observed, whereas treatments with Alda-1 and an ROS scavenger reversed these findings. Through transcriptome analysis, the authors then identified activation of Jun N-terminal kinase (JNK) with subsequent activation of c-Jun-related apoptotic signaling following ischemic stress. The restoration of cell viability with the administration of JNK inhibitor validated the proposed pathway and demonstrated unique insight into the ischemic consequences in patients with an ALDH2 polymorphism using an iPSC model.
DISCUSSION
Important advances in the iPSC field have provided new research capacity to study metabolic disorders and associated heart disease in ways previously unavailable in animal or alternative in-vitro models. Human iPSC-CM platforms provide a powerful tool that allows drug screening specific to individual patients with variable disease expression. However, these advances have not arisen without additional questions.
Despite the increased potential to recapitulate disease, there remain significant challenges in reconstitution of metabolic mitochondrial diseases [39] . Phenotypes of Leigh and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS) syndrome were successfully studied in iPSC-derived skeletal and neuronal cells demonstrating significant mitochondrial dysfunction [40] . Carnitine palmitoyltransferase II, an enzyme essential for fatty acid transport, was also reconstituted and treated in iPSCderived skeletal muscle cells [41] . However, methodologies to produce cardiomyocytes in these diseases have been hindered by the overwhelming cell death occurring during differentiation to cardiomyocytes. Further efforts are warranted to optimize differentiation conditions to generate iPSC-CM platforms that will successfully recapitulate cardiac disease phenotypes associated with mitochondrial diseases, which include, but are not limited to, Sengers, Kearns-Sayre, Leigh, and MELAS syndromes and carnitine palmitoyltransferase II deficiency [42] [43] [44] .
The immature fetal-like characteristics of iPSC-CMs have also been a cause of concern for investigators and their direct application to adult heart disease [6 & ]. Efforts to develop mature cardiomyocytes have been successful with prolonged culture protocols and alterations in extracellular matrix dynamics [45] . However, fetal characteristics may pose an advantage for studying IEM where diseases commonly present early in life. Interestingly, it has also been postulated that iPSC-CMs allow characterization of metabolic profiles earlier on during differentiation and are not maturation dependent. This is evident from several studies presented in this review, where metabolic markers were commonly analyzed rather than cardiac sarcomere markers.
A progressing area in the cardiac stem cell field is the application of genome editing technologies, including zinc finger nucleases, transcription activator-like effector nucleases, and CRISPR/Cas9 [46] . Genome editing provides the opportunity to introduce and repair mutations, thereby establishing and rescuing a disease phenotype [47, 48] . This approach eliminates a need to recruit patients with specific mutations and also bypasses the step required to reprogram adult somatic stem cells to iPSCs. Additionally, genome editing can directly establish causation between a mutation and its disease by creating genome-edited isogenic cells with wildtype protein [15] . The culmination of these features provides the potential to pharmaceutically target specific disease-inducing mutations. A recent study showed significant reduction in low-density lipoprotein cholesterol with in-vivo genome editing of loss of function mutations in the proprotein convertase subtilisin/kexin type 9 gene [49] . This exciting result demonstrates the tremendous applications of both genome editing and iPSC models for drug discovery.
CONCLUSION
Undoubtedly, both iPSCs and iPSC-CMs have allowed recapitulation of previously challenging phenotypes to model in vivo and in vitro. To date, several IEM and metabolic syndromes have been recapitulated in a patient-specific manner and have provided insight into disease mechanisms as well as identification of novel drug targets. Advances in genome editing technologies have provided further capacity to induce and rescue a disease phenotype in vitro with potential for in-vivo application. These innovations provide optimism for further exploration of additional metabolic disorders, such as mitochondrial disorders, that remain challenging to model in iPSC-CMs.
